Travere Therapeutics (TVTX) Misses Q1 EPS by 17c

Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.40), $0.17 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $127.2 million versus the consensus estimate of $137.34 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Krait Critical Minerals closes $1.22M first tranche of placement
• Future Money Acquisition gets Nasdaq notice over late 10-Q filing